These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 27633081

  • 21. Antiatherogenic effects of liraglutide in hyperglycemic apolipoprotein E-null mice via AMP-activated protein kinase-independent mechanisms.
    Koshibu M, Mori Y, Saito T, Kushima H, Hiromura M, Terasaki M, Takada M, Fukui T, Hirano T.
    Am J Physiol Endocrinol Metab; 2019 May 01; 316(5):E895-E907. PubMed ID: 30860874
    [Abstract] [Full Text] [Related]

  • 22. Glucagon-Like Peptide-1 Receptor Agonist Prevented the Progression of Hepatocellular Carcinoma in a Mouse Model of Nonalcoholic Steatohepatitis.
    Kojima M, Takahashi H, Kuwashiro T, Tanaka K, Mori H, Ozaki I, Kitajima Y, Matsuda Y, Ashida K, Eguchi Y, Anzai K.
    Int J Mol Sci; 2020 Aug 10; 21(16):. PubMed ID: 32785012
    [Abstract] [Full Text] [Related]

  • 23. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial.
    Farr OM, Sofopoulos M, Tsoukas MA, Dincer F, Thakkar B, Sahin-Efe A, Filippaios A, Bowers J, Srnka A, Gavrieli A, Ko BJ, Liakou C, Kanyuch N, Tseleni-Balafouta S, Mantzoros CS.
    Diabetologia; 2016 May 10; 59(5):954-65. PubMed ID: 26831302
    [Abstract] [Full Text] [Related]

  • 24. The effects of liraglutide in mice with diet-induced obesity studied by metabolomics.
    Bugáňová M, Pelantová H, Holubová M, Šedivá B, Maletínská L, Železná B, Kuneš J, Kačer P, Kuzma M, Haluzík M.
    J Endocrinol; 2017 Apr 10; 233(1):93-104. PubMed ID: 28138003
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Novel lipid side chain modified exenatide analogs emerged prolonged glucoregulatory activity and potential body weight management properties.
    Li C, Cai X, Dai Y, Liu C, Bi X, Zhou J, Li Q, Sun L, Huang W, Hou Z, Qian H.
    Bioorg Med Chem; 2019 Oct 15; 27(20):115070. PubMed ID: 31471103
    [Abstract] [Full Text] [Related]

  • 33. TCDD modulation of gut microbiome correlated with liver and immune toxicity in streptozotocin (STZ)-induced hyperglycemic mice.
    Lefever DE, Xu J, Chen Y, Huang G, Tamas N, Guo TL.
    Toxicol Appl Pharmacol; 2016 Aug 01; 304():48-58. PubMed ID: 27221631
    [Abstract] [Full Text] [Related]

  • 34. Reduction of oxidative stress by a new low-molecular-weight antioxidant improves metabolic alterations in a nonobese mouse diabetes model.
    Novelli M, D'Aleo V, Lupi R, Paolini M, Soleti A, Marchetti P, Masiello P.
    Pancreas; 2007 Nov 01; 35(4):e10-7. PubMed ID: 18090226
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Different effects of two dipeptidyl peptidase-4 inhibitors and glimepiride on β-cell function in a newly designed two-step hyperglycemic clamp.
    Zhang Y, Chi J, Wang W, Hong J, Gu W, Wang B, Ning G.
    J Diabetes; 2015 Mar 01; 7(2):213-21. PubMed ID: 24889731
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.